Active, Not Recruiting
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
- Locations
-
- GSK Investigational Site Tucson, Arizona, United States
- GSK Investigational Site Pueblo, Colorado, United States
- GSK Investigational Site Detroit, Michigan, United States
- GSK Investigational Site Omaha, Nebraska, United States